# A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)

> **NCT05027204** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 94 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05027204
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-04
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2022-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027204, "A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05027204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*